Methodology of screening for albuminuria

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2109-2111

  Gansevoort, R T ^a   Lambers, Heerspink ^a   Witte, E C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Albuminuria; Creatinine; Micro albuminuria; Screening

Indexed keywords

ALBUMIN;

ALBUMINURIA; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIAGNOSTIC VALUE; ENDOTHELIUM LESION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEDICAL SOCIETY; METHODOLOGY; MICROALBUMINURIA; NOTE; PATIENT IDENTIFICATION; PATIENT MONITORING; PRIORITY JOURNAL; SCREENING; SENSITIVITY AND SPECIFICITY; URINALYSIS; VASCULAR ENDOTHELIUM;

ALBUMINS; ALBUMINURIA; CHEMISTRY, CLINICAL; CREATINE; HUMANS; KIDNEY DISEASES; MASS SCREENING; REFERENCE VALUES; TIME FACTORS;

EID: 34547851727     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm267     Document Type: Note

References (15)

1. Hillege HL, Fidler V, Diercks GF et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population. Circulation 2002; 106: 1777-1782
2. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110: 32-35
3. Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: Association with incident coronary heart disease and death. Hypertension 2005; 46: 33-37
4. Klausen KP, Scharling H, Jensen JS. Very low level of microalbuminuria is associated with increased risk of death in subjects with cardiovascular or cerebrovascular diseases. J Intern Med 2006; 260: 231-237
5. Levey AS, Eckartd KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100
6. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, classification and stratification. Part 5: Evaluation of laboratory measurements for clinical assessment of kidney disease. Guideline 5, assessment of proteinuria/albuminuria. http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p5_lab_g5.htm (11 April 2005)
7. Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross-sectional longitudinal study of spot morning urine protein:cReatinine ratio, 24hr urine protein, excretion, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes. Br Med J 1998; 316: 504-509
8. Jafar TH, Chaturvedi N, Hatcher J, Levey AS. Use of albumin:cReatinine ratio and albumin concentration as a screening test for albuminuria in an Indo-Asian population. Nephrol Dial Transplant (in press)
9. Bakker AJ. Detection of microalbuminuria. Receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 1999; 22. 307-313
10. Gansevoort RT, Verhave JC, Hillege HL et al. for the PREVEND Study Group, The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int 2005; 94: S28-S35
11. Dyer AR, Greenland P, Elliott P et al. INTERMAP Research Group. Evaluation of measures of urinary albumin excretion in epidemiologic studies. Am J Epidemiol 2004; 160: 1122-1131
12. Gansevoort RT, Brinkman J, Bakker SJ, De Jong PE, de Zeeuw D. Evaluation of measures of urinary albumin excretion. Am J Epidemiol 2006; 164: 725-727
13. Asselbergs FW, Diercks GF, Hillege HL et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with micro-albuminuria. Circulation 2004; 110: 2809-2816
14. Atthobari J, Asselbergs FW, Boersma C et al. PREVEND IT Study Group. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmaco-economic analysis linked to the PREVEND study and the PREVEND Intervention Trial. Clin Ther 2006; 28: 432-444
15. Postma MJ, Boersma C, Gansevoort RT. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. Nephrol Dial Transplant 2007 (in press)